Cosmos Health enters manufacturing agreement with Libytec

Cosmos Health (COSM) ‘s wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical. Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements. The product will be distributed and commercially promoted in the Greek market by Libytec Pharmaceutical S.A., with the agreement providing for firm minimum committed production volumes of 591,500 units and expected cumulative production volumes over a five-year period anticipated to exceed 1.2 million units, subject to market demand and commercial performance.